Drugs / Senna
Senna
Trials 9 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT07604025 | Jul 2026 → Jul 2027 expected | constipation disorder | Shaare Zedek Medical Center | Not yet recruiting | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT03342157 | Apr → Aug 2018 | gastroparesis | Wake Forest University Health Sciences | Terminated | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT00571896 | Jan 2008 → Jun 2009 | constipation disorder | Hartford Hospital | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT00275184 | Jan 2006 → ? | myelodysplastic syndrome, small intestine disorder | London North West Healthcare NHS Trust | Unknown | No outcome recorded |
| Phase 42 trials | ||||||
| Phase 4 | NCT06825260 | Apr 2025 → Mar 2027 expected | outlet dysfunction constipation | St. Joseph's Health, New York | Recruiting | No outcome recorded |
| Phase 4 | NCT01189409 | Jun 2010 → Dec 2017 | cancer, constipation disorder | British Columbia Cancer Agency | Terminated | No outcome recorded |
| Phase not applicable3 trials | ||||||
| — | NCT03593252 | Jan 2022 → Jan 2024 | Hirschsprung disease, inflammatory bowel disease, meconium ileus, necrotizing enterocolitis | McMaster University | Unknown | No outcome recorded |
| — | NCT03501498 | Apr 2017 → May 2018 | — | University Hospital Plymouth NHS Trust | Completed | No outcome recorded |
| — | NCT02383758 | Feb 2015 → Jan 2017 | autism spectrum disorder, bowel dysfunction | Emory University | Completed | No outcome recorded |
Also used as a comparator or background therapy in 13 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT01695850 Comparator | Jun 2013 → Aug 2015 | constipation disorder | Hong Kong Baptist University | Completed | No outcome recorded |
| Phase 46 trials | ||||||
| Phase 4 | NCT03148002 Comparator | Jul 2017 → Apr 2018 | constipation disorder | Nova Scotia Health Authority | Completed | No outcome recorded |
| Phase 4 | NCT02977286 Background | Jan 2017 → Oct 2019 | constipation disorder | Tufts Medical Center | Terminated | No outcome recorded |
| Phase 4 | NCT02665624 Comparator | Apr → Jun 2015 | — | Camlıca Erdem Hospital | Completed | No outcome recorded |
| Phase 4 | NCT01773096 Background | May 2013 → May 2015 | constipation disorder | Shriners Hospitals for Children | Completed | No outcome recorded |
| Phase 4 | NCT01140295 Comparator | Sep 2010 → May 2011 | — | Children's Hospital of Philadelphia | Terminated | No outcome recorded |
| Phase 4 | NCT00460837 Comparator | Nov 2007 → Mar 2009 | colorectal cancer | London North West Healthcare NHS Trust | Withdrawn | No outcome recorded |
| Phase not applicable6 trials | ||||||
| — | NCT07426133 Background | Mar → Dec 2025 | — | Shaukat Khanum Memorial Cancer Hospital & Research Centre | Completed | No outcome recorded |
| — | NCT02481219 Background | May 2015 → Jan 2016 | colorectal cancer | Medtronic - MITG | Completed | No outcome recorded |
| — | NCT02239510 Comparator | Sep 2014 → Jun 2016 | constipation disorder | TriHealth Inc. | Terminated | No outcome recorded |
| — | NCT02008864 Comparator | Aug 2011 → Sep 2012 | end stage renal failure | Shiraz University of Medical Sciences | Completed | No outcome recorded |
| — | NCT00662363 Comparator | Apr 2008 → Oct 2011 | constipation disorder | Shirley Ryan AbilityLab | Completed | No outcome recorded |
| — | NCT00902031 Background | Apr 2006 → Oct 2010 | constipation disorder | University of Alberta | Completed | No outcome recorded |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 22 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Senna | “Two common treatments are polyethylene glycol 3350 (PEG), an osmotic laxative, and Senna, a plant-based stimulant laxative.” NCT07604025 ↗ |
| Known as | Cassia senna L. | “In Iranian traditional medicine Cassia senna L. is used for healing uremic pruritus .” NCT02008864 ↗ |
| Known as | Sennoside | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00902031 ↗ |
| Action | Activate | “Senna is a stimulant laxative that increases propulsive peristaltic activity of the colon through local effects on the mucosa.” NCT00662363 ↗ |
| Modality | Traditional medicine (herbal / TCM) | “In Iranian traditional medicine Cassia senna L. is used for healing uremic pruritus .” NCT02008864 ↗ |
| Route | Oral | “Sennoside: will be given in tablet form (8.6 mg), 1-3 tablets taken 1-3 times daily for 10 days.” NCT00902031 ↗ |
| Target | TNF | “may attenuate uremic pruritus by decreasing serum IL-2, IFN-γ and TNF-α” NCT02008864 ↗ |